Sirion Therapeutics, Inc., an ophthalmic-focused pharmaceutical company, announced today that it has reached an exclusive licensing agreement with Senju Pharmaceutical Co., Ltd. of Japan for the U.S. rights to develop and market a topical ophthalmic emulsion containing the steroid compound difluprednate for the treatment of inflammatory eye diseases.
Drug Newswire